The company is planning to sell 390m shares in the base offering and 59m in the greenshoe. The total offering represents 53% of the company. The price range for the deal will be announced on March 26.
Of the issue, about half will be capital increase and half will be secondary. "The company is going to use the proceeds to finance internal growth, enter further collaboration arrangements and commission scientific and clinical surveys," said a banker close to the deal.
Bank Sarasin, Lombard Odier and Kantonalbank are co-managers.